文献速递新发突发、热带与寄生虫病

青蒿琥酯-本芴醇与双氢青蒿素-哌喹治疗乌干达儿童无并发症疟疾的疗效比较

Comparative Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Ugandan Children.
PubMed 文献 · J Infect Dis · 2019-01-01

该随机单盲临床试验在乌干达3个中心纳入599例6-59月龄无并发症恶性疟患儿,比较青蒿琥酯-本芴醇(AL)与双氢青蒿素-哌喹(DHA-PQ)的42天疗效。结果显示DHA-PQ组复发性寄生虫血症风险显著低于AL组(26.0% vs 47.0%,P < .001),两种方案均未选择与耐药相关的pfcrt或pfmdr1多态性。

要点

  • DHA-PQ较AL显著降低42天复发性寄生虫血症风险。
  • 两种方案复燃感染均少见,AL与DHA-PQ分别1.1%和2.2%。
  • 两方案均未选择pfcrt或pfmdr1耐药相关多态性。

核心结论

  • 在乌干达儿童中,AL和DHA-PQ对无并发症疟疾仍有效。
  • DHA-PQ组42天复发性寄生虫血症风险低于AL组(26.0% vs 47.0%,P < .001)。
  • 两种方案均未选择与耐药相关的pfcrt或pfmdr1多态性。

研究设计与样本

  • 随机、单盲临床试验,在乌干达3个中心开展。
  • 纳入599例6-59月龄无并发症恶性疟患儿,578例完成随访。
  • 患儿随机接受AL或DHA-PQ治疗,随访42天。

主要发现

  • 无早期治疗失败。
  • 42天复发性寄生虫血症风险DHA-PQ组为26.0%,AL组为47.0%(P < .001)。
  • 复燃感染率DHA-PQ组1.1%,AL组2.2%(P = .25)。
  • 两种方案均未选择pfcrt或pfmdr1耐药相关多态性。

关键数值与推荐

  • 主要终点为复发性寄生虫血症风险,包括未调整和调整后(区分复燃与新感染)。
  • 评估了研究方案对疟原虫耐药相关遗传多态性的选择作用。

临床怎么用

  • 在乌干达儿童无并发症疟疾治疗中,AL和DHA-PQ均可作为有效方案。
  • DHA-PQ在降低复发性寄生虫血症方面优于AL,但需结合当地耐药监测选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In Uganda, artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DHA-PQ) showed excellent treatment efficacy for uncomplicated malaria in prior trials. Because the frequency of resistance to artemisinins and piperaquine is increasing in Southeast Asia and the prevalence of Plasmodium falciparum polymorphisms associated with resistance has changed, we reassessed treatment efficacies at 3 sites in Uganda. METHODS: For this randomized, single-blinded clinical trial, children aged 6-59 months with uncomplicated falciparum malaria were assigned treatment with AL or DHA-PQ and followed for 42 days. Primary end points were risks of recurrent parasitemia, either unadjusted or adjusted to distinguish recrudescence from new infection. We assessed selection by study regimens of relevant P. falciparum genetic polymorphisms associated with drug resistance. RESULTS: Of 599 patients enrolled, 578 completed follow-up. There were no early treatment failures. The risk of recurrent parasitemia was lower with DHA-PQ as compared to AL at all 3 sites at 42 days (26.0% vs 47.0%; P < .001). Recrudescent infections were uncommon in both the DHA-PQ and AL arms (1.1% and 2.2%, respectively; P = .25). Neither regimen selected for pfcrt or pfmdr1 polymorphisms associated with drug resistance. CONCLUSIONS: AL and DHA-PQ remain effective for the treatment of malaria in Uganda. Neither regimen selected for genetic polymorphisms associated with drug resistance. CLINICAL TRIALS REGISTRATION: ISRCTN15793046.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Yeka A, Wallender E, Mulebeke R, et al. Comparative Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Ugandan Children. J Infect Dis. 2019. PMID: 30418593. doi:10.1093/infdis/jiy637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。